China joins US and Japan in approving Alzheimer’s drug Leqembi developed by Eisai and Biogen

China has approved a drug to treat Alzheimer’s, becoming only the third country after the US and Japan to fast track its sale to treat the irreversible and progressive brain disorder.

The nation’s drugs regulator on Tuesday said Leqembi, an antibody that has shown to slow progression of the disease for people in the early stages of Alzheimer’s, can be sold in the country.